GEMINA LABS APPOINTS DR MICHAEL SHANNON AS CHAIR OF CLINICAL ADVISORY BOARD

December 20, 2022

GEMINA LABORATORIES LTD. 

News Release 

GEMINA LABS APPOINTS DR MICHAEL SHANNON AS CHAIR OF CLINICAL ADVISORY BOARD 

December 20, 2022, Vancouver, British Columbia: Gemina Laboratories Ltd. (CSE: GLAB) (FRA:8I7) (the  “Company” or “Gemina”) is delighted to announce Dr. Michael Shannon has been appointed to constitute  and Chair the Company’s Clinical Advisory Board. 

Dr. Shannon is one of Canada’s pre-eminent public health leaders. He spent 31 years in the Canadian  Forces, retiring at the rank of Commodore (Brigadier General equivalent) as Deputy Surgeon General for  Canada. In 1996 he assumed responsibilities within Health Canada for re-organizing the Canadian blood  system. Subsequently, he was appointed Director General for the Laboratory Centre for Disease Control,  a position he held for three years. Later he served as an Audit Principal and Senior Medical Advisor to the  Canadian Auditor General and then accepted responsibilities for rebuilding the Emergency Medical  Response System within the newly formed Public Health Agency of Canada. In this regard and under his  direction, the largest emergency medical response exercise in the history of the country, involving the overnight construction of a mobile hospital, hundreds of doctors and thousands of patients, was 

successfully conducted in Toronto. 

Outside of public service, Dr Shannon has been an advisor to numerous life science companies in both  therapeutic and other bioscience applications. His formal training includes a medical degree from Queen’s  University, and post-graduate degrees in neurochemistry and physiology. He has been actively engaged  in applied medical research within these areas for 30 years. 

Dr. Shannon stated, “I am delighted to work with Gemina at this stage of the its development. The past  three years have demonstrated the utility of point of care testing in public health, primary care and home  settings. The Gemina team has a compelling plan to develop a portfolio of accurate and reliable tests with  improved ease-of-use. I look forward to building an active clinical advisory board that will provide Gemina  with insights and knowledge important for the success of its products and technologies.” 

Brian Firth commented, “Gemina’s product development trajectory has reached a stage where it’s  important to establish a clinical advisory board, to ensure that the Company is positioned to make the  best possible decisions when it comes to its product-market choices. We’re incredibly pleased to be able  to welcome Dr. Shannon to the Company. He is an immensely distinguished practitioner with an  extraordinary insight into both national and international public health concerns, including global threats  to public health such as COVID-19. I’m looking forward to working with him to build Gemina’s Clinical  Advisory Board in the weeks and months to come.” 

On Behalf of the Board of Directors 

John Davies 

Chairman 

Gemina Laboratories Ltd.

About Gemina Laboratories Ltd. 

Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary  chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Our technology drives testing platforms that are fast, affordable and accurate, and  easily self-administered. Our development pipeline includes platforms for the rapid testing of COVID-19,  influenza and other viruses. Additional information on the Company can be found at  www.geminalabs.com. 

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined  in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy  of this Release. 

Forward Looking Statements 

This news release includes forward-looking information and statements, which may include, but are not  limited to, information and statements regarding or inferring the future business, operations, financial  performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company.  Such statements include statements regarding the anticipated terms of any proposed transaction or  engagement. Information and statements which are not purely historical fact are forward-looking  statements. Forward-looking information and statements involve and are subject to assumptions and  known and unknown risks, uncertainties, and other factors which may cause actual events, results,  performance, or achievements of the Company to be materially different from future events, results,  performance, and achievements expressed or implied by forward-looking information and statements  herein. Although the Company believes that any forward-looking information and statements herein are  reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such  information and statements, there can be no assurance that any such forward-looking information and  statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation  of such risks and uncertainties and should not place undue reliance upon such forward-looking  information and statements. Furthermore, the Company is presently unable to fully quantify the impact  that the Covid-19 pandemic will have on its operations and recognizes that certain eventualities may  affect planned or assumed performance moving forward. As such, any forward-looking information and  statements herein are made as of the date hereof, and except as required by applicable laws, the  Company assumes no obligation and disclaims any intention to update or revise any forward-looking  information and statements herein or to update the reasons that actual events or results could or do differ  from those projected in any forward looking information and statements herein, whether as a result of  new information, future events or results, or otherwise, except as required by applicable laws.  

For more information regrading the Company, please contact: 

Brian Firth, CEO 

Email: investor@geminalabs.com

Receive Company Updates
Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.

Press and Updates

GEMINA LABS ANNOUNCES STRATEGIC STAKE IN BRITISH RAPID TEST OPTIMIZER RAPIVD LIMITED

December 7, 2022
Read More

GEMINA LABS ENTERS INTO LICENSE AND MANUFACTURING AGREEMENTS

October 6, 2022
Read More

GEMINA LABS PRESENTS AT THE H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

September 12, 2022
Read More

Enter Your Email To Sign Up For Campaign Updates. 

Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.